Neuron23
San Francisco
About Neuron23
Neuron23 is a developer of drugs intended to treat Parkinson's disease and Alzheimer's disease. The company was founded in 2018 and is based in San Francisco, California, United States.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $310.0M
- Funding stage: Late Stage Venture
- Last round: Series D (Jun 2025)
- Website: neuron23.com
Industries & Categories
Health Care, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/neuron23-120593 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.